Table 3.

Comparison of change in atherosclerosis markers between SGLT2i and non-SGT2i.

	SGLT2i N = 54	SGLT2i		p1	Non-SGLT2i N = 59	Non-SGLT2i		p2	p3
		SGLT2i D N = 30	SGLT2i non-D N = 24			Non-SGLT2i D N = 34	Non-SGLT2i non-D N = 25
∆FMD (mm)	0.08 ± 0.11	0.05 ± 0.11	0.10 ± 0.10	0.11	−0.03 ± 0.13	−0.05 ± 0.13	−0.008 ± 0.12	0.18	<0.001
∆FMD%	1.78 ± 3.63	1.38 ± 3.19	2.85 ± 3.46	0.05	−0.88 ± 4	−1.34 ± 3.72	−0.25 ± 4.33	0.31	<0.001
∆CIMT (mm−1)	−0.12 ± 1.03	−0.24 ± 0.8	0.02 ± 1.2	0.38	−0.03 ± 1.31	−0.12 ± 0.73	0.08 ± 1.85	0.57	0.7
∆HBA1C%	−0.27 ± 1.55	−1.01 ± 1.18	−0.31 ± 1.50	0.16	−0.08 ± 1.63	−0.36 ± 2.20	0.18 ± 0.29	0.34	0.61
∆Uric acid (mmol/L)	−51.3 ± 70.9	−41.89 ± 68.34	−125 ± 170.26	0.16	−16.3 ± 99.4	−23.34 ± 115.78	−7.82 ± 77.54	0.63	0.08
∆NLR	−0.56 ± 6.92	−0.67 ± 2.58	−0.41 ± 10.29	0.91	−0.54 ± 2	−0.31 ± 1.85	−0.88 ± 2.22	0.38	0.98
∆Hematocrit (%)	0.59 ± 5.23	0.67 ± 4.92	−2.77 ± 10.24	0.22	1.92 ± 4.93	2.28 ± 4.25	1.37 ± 5.89	0.57	0.27
∆Hemoglobin (g/dL)	−0.16 ± 1.66	−0.02 ± 1.55	−0.55 ± 1.66	0.32	0.27 ± 1.54	0.30 ± 1.17	0.21 ± 2.02	0.87	0.18
∆ Total cholesterol (mmol/L)	−0.75 ± .12	−0.58 ± 1.32	−0.97 ± 0.75	0.24	−0.39 ± 1.19	−0.38 ± 1.29	−0.40 ± 1.04	0.96	0.15
∆Triglycerides (mmol/L)	−0.09.98	−0.27 ± 0.83	0.28 ± 1.22	0.13	−0.23 ± 0.63	−0.31 ± 1.85	−0.88 ± 2.22	0.28	0.43

Δ = change from baseline, CIMT = carotid intima media thickness, FMD = flow mediated dilation, FMD% = FMD rate, HBA1C = glycated hemoglobin, NLR = neutrophils to lymphocyte ratio, p1 = difference between SGLT2i D and SGLT2i non-D groups, p2 = difference between non-SGLT2i D and non-SGLT2i non-D groups, p3 = difference between SGLT2i and non-SGLT2i groups, SBP = systolic blood pressure, SGLT2i = sodium glucose cotransporter 2 inhibitors (group designation).